In a decisive move, the Tamil Nadu government announced on Monday, October 13, 2025, that it has permanently revoked the manufacturing license of Sresan Pharmaceuticals. The company, based in Tamil Nadu, has been ordered to immediately cease all operations following its involvement in producing the dangerously adulterated ‘Coldrif’ cough syrup.
An inspection by the State Drug Control Department revealed alarming findings: the ‘Coldrif’ cough syrup contained a shocking 48.6% concentration of Diethylene Glycol (DEG), a highly toxic chemical. This specific medicine has been tragically linked to the deaths of several children in Madhya Pradesh, highlighting the severe public health risk posed by the product.
Further investigations by officials uncovered pervasive issues within Sresan Pharmaceuticals, including a severe lack of adherence to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). Inspectors documented more than 300 critical and major violations, indicating a systemic failure in quality control and safety standards.
Adding to the legal consequences, G. Ranganathan, the owner of the company, was recently apprehended by a special investigation team from Madhya Pradesh in connection with the scandal.
The Enforcement Directorate also conducted searches at the premises of Sresan Pharmaceuticals and related officials as part of a Prevention of Money Laundering Act (PMLA) case, signaling a broader investigation into the firm’s financial dealings.
A government statement confirmed, ‘The drug manufacturing license of Sresan Pharmaceuticals has been completely cancelled, and the company has been closed.’ The state has also initiated comprehensive inspections of all other drug manufacturing companies across Tamil Nadu to prevent similar incidents and reinforce stringent safety regulations.